Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
StromaForte in Knee Osteoarthritis
NCT06084988Phase 2Completed
- Sponsor
- Cellcolabs
- Start
- Nov 2023
- Primary completion
- Oct 2024
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of StromaForte in knee osteoarthritis (OA), sponsored by Cellcolabs. Primary endpoint: Safety and Tolerability Assessed by Adverse Events at 168 days. Started Nov 2023; status: completed.
02
Drugs
StromaForte
03
Conditions
knee osteoarthritis (OA)
Beyond the preview
Go deeper on NCT06084988.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06084988.